NCT04227106View on ClinicalTrials.gov

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

October 18, 2022

Study Completion Date

October 18, 2022

Conditions
Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

EB-101

autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7

Trial Locations (2)

94063

Stanford University, Redwood City

01605

University of Massachusetts Medical School, Worcester

Sponsors
All Listed Sponsors
lead

Abeona Therapeutics, Inc

INDUSTRY

NCT04227106 - Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Biotech Hunter | Biotech Hunter